News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Last Patient in Isotechnika Inc.'s Phase 2b Kidney Transplant Trial Completes Six Month Treatment
January 3, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
EDMONTON, Jan. 3 /CNW/ - Isotechnika Inc. (TSX:ISA) announced today that the last patient enrolled in the Company's Phase 2b kidney transplant trial has completed the six month trial.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 2
MORE ON THIS TOPIC
Insights
From Grants to Family Offices: Building a Unified Financing Strategy in Biotech
March 5, 2026
·
1 min read
·
Jennifer Smith-Parker
Podcast
UniQure’s Delay, REGENXBIO’s Rejection Explained, Sarepta’s Ingram Steps Down, More
March 4, 2026
·
1 min read
·
Heather McKenzie
Insights
Rethinking Biotech’s Valley of Death as Federal Grants and Family Offices Step In
March 4, 2026
·
3 min read
·
Jennifer Smith-Parker
IN PARTNERSHIP WITH MEDSIR
Webinar: The Future is Collaborative: Transforming Clinical Trials
March 3, 2026
·
1 min read
·
BioSpace Insights
